Trigeminal neuralgia

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
ATC code not specified 1
M Musculoskeletal (ATC M) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Supportive / diluent 1 substance
Phase III: 1 Phase II/III: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Rigshospitalet Academic
    BOTULINUM TOXIN TYPE A; SODIUM CHLORIDE
    2023-504567-17-00 1 country 2023 n=80
    Recruiting

Phase II/III

1 trial
  • Noema Pharma AG Commercial
    BASIMGLURANT
    2024-514497-41-00 5 countries 2022 n=111
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Noema Pharma AG Commercial 1 Phase II/III 0
Rigshospitalet Academic 1 Phase III 1
New trials by year
2022
1
2023
1
← All indication landscapes